Phase 3 Brain Cancer Trial, Recruiting NCT05768490 Sponsor: Sun Yat-sen University Condition: Brain Cancer
Back to Brain Cancer

Phase 3 Brain Cancer Trial, Recruiting

NCT05768490
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer, confirmed through a tissue or cell sample test
  • People who have been newly diagnosed with a small number of brain metastases (cancer that has spread to the brain) — specifically fewer than 5 spots in the brain, confirmed by MRI, with no brain treatment given yet, at least one spot measuring 5mm or larger, and all spots at least 3mm away from the optic nerve and brainstem
  • People whose cancer has a specific gene change called an EGFR mutation (exon 19 deletion or exon 21 L858R)
  • People who have not previously been treated with any EGFR-targeting drugs or similar targeted therapy medicines
  • People aged between 18 and 75 years old

Who may not be able to join:

  • People who have had, or currently have, another type of cancer elsewhere in the body (with the exception of certain easily treated skin cancers or early-stage cervical changes)
  • People who have already received radiation treatment to the brain before entering the trial
  • People whose lung cancer has not spread to other parts of the body and whose lung tumour has been assessed as removable by surgery
  • People who have previously received EGFR-blocking treatments or any other systemic (whole-body) anti-cancer therapy
  • People who have a history of lung scarring or inflammation conditions, including interstitial lung disease, drug-related lung damage, radiation-related lung damage requiring steroid treatment, or signs of active lung scarring seen on a CT scan
  • People who are pregnant or breastfeeding
  • People for whom an MRI scan is not safe or suitable
  • People who are unable to swallow tablets, require nutrition through a drip, have had surgery that affects how the gut absorbs medicines, or have an active stomach or bowel ulcer
  • People who, in the opinion of the research team, cannot safely receive brain radiation due to other conditions affecting the head or face
  • People with unstable or poorly controlled health conditions, such as active infection, high blood pressure that is difficult to control, unstable chest pain, heart failure, or significant liver, kidney, or metabolic disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Likun Chen, sunyat-sen university cancer center

Phone: +8613798019964

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
15 March 2023
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov